Atlas Trials

Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL

Clinical trial NCT07538180 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT07538180
Sponsor
Sun Yat-sen University
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Newly Diagnosed MYC/BCL2 Double-expressor DLBCL
Start date
2025-10-30
Primary completion
2027-12-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.